To the Editor:Serum alkaline phosphatase (ALP) is an important bone turnover marker in chronic kidney disease (CKD) patients, with studies indicating that higher serum ALP levels are associated with increased mortalit...To the Editor:Serum alkaline phosphatase (ALP) is an important bone turnover marker in chronic kidney disease (CKD) patients, with studies indicating that higher serum ALP levels are associated with increased mortality in hemodialysis (HD) patients.[1] Our previous study also showed that higher serum ALP levels were independently associated with all-cause and cardiovascular mortality in peritoneal dialysis (PD) patients.展开更多
基金grants from the Natural Science Foundation of China (Nos.81774069,81570614, 81600.516,81603437)National Key Research and Development Program (No.2016YFC0906101)+3 种基金Program of the Ministry of Health of China (No.201502023), the Guangdong Science Foundation of China (Nos. 2014B020212020,2017A050503003,2017B020227006)Foundation of Guangdong Key Laboratory of Nephrology (No.2017B030314019)the Guangzhou Committee of Science and Technology,China (No.201704020167)and the Medical and Health Program of Zhejiang Province, China (No.2016KYB018).
文摘To the Editor:Serum alkaline phosphatase (ALP) is an important bone turnover marker in chronic kidney disease (CKD) patients, with studies indicating that higher serum ALP levels are associated with increased mortality in hemodialysis (HD) patients.[1] Our previous study also showed that higher serum ALP levels were independently associated with all-cause and cardiovascular mortality in peritoneal dialysis (PD) patients.
